Curis to Present at the Leerink Swann & Company/MEDACorp Inaugural Healthcare Conference
Thursday February 24, 8:30 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 24, 2005--Curis, Inc. (NASDAQ: CRIS - News) announced today that Daniel Passeri, Curis' President and Chief Executive Officer, will present an overview of the status of Curis' business and collaborations at the upcoming Leerink Swann/MEDACorp Inaugural Healthcare Conference to be held on Tuesday, March 1, at The Plaza Hotel in New York City. Mr. Passeri's presentation will be at 9:00 A.M. EST in the Fragonard Room.
The presentation will be webcast live at:
wsw.com
It will be archived for 30 days following the conference. Shortly after Mr. Passeri's remarks have concluded, the presentation will also be available on the Investor Relations section of Curis' website at www.curis.com.
About Curis, Inc.
Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer (under partnership with Genentech, which also includes a co-development collaboration between Curis and Genentech for a basal cell carcinoma product candidate), kidney disease (licensed to Ortho Biotech, a subsidiary of Johnson & Johnson), neurological disorders (partnered with Wyeth Pharmaceuticals), hair growth, and cardiovascular disease. For more information, please visit the Curis web site at www.curis.com. |
